MammaPrint

Agendia

Innovation image

Within our societies, it is widely recognized that breast cancer is one of the most common cancers amongst women. After the diagnosis, patients and physicians need to decide which next steps need to be taken. To find out what would be the best kind of treatment, MammaPrint is the first FDA-cleared breast cancer genomic test that classifies an early stage breast cancer tumor as having either a Low Risk or High Risk of recurrence. Based on these findings, the physician can decide on the most appropriate treatment for the patient's condition.

Details

Sector - Health
Location Amsterdam
Year 2004
Reference Visit website

Interact